---
title: "HUIYU PHARMACEUTICAL and its subsidiaries have obtained overseas listing licenses for multiple products"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257335026.md"
description: "HUIYU PHARMACEUTICAL and its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. recently obtained overseas marketing approvals for multiple products, including injectable paclitaxel (albumin-bound), injectable cyclophosphamide, paclitaxel injection, injectable zoledronic acid concentrated solution, and injectable azacitidine, approved by the drug regulatory authorities of Denmark, Germany, Uzbekistan, and Bangladesh, respectively"
datetime: "2025-09-15T10:02:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257335026.md)
  - [en](https://longbridge.com/en/news/257335026.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257335026.md)
---

# HUIYU PHARMACEUTICAL and its subsidiaries have obtained overseas listing licenses for multiple products

According to the Zhitong Finance APP, HUIYU PHARMACEUTICAL (688553.SH) announced that the company and its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. recently received marketing approvals for their products, including injectable paclitaxel (albumin-bound), injectable cyclophosphamide, paclitaxel injection, injectable zoledronic acid concentrated solution, and injectable azacitidine, issued by the Danish Medicines Agency, the German Federal Institute for Drugs and Medical Devices, the Republic of Uzbekistan's Drug Regulatory Authority, and the Bangladesh Drug Regulatory Authority, respectively

### Related Stocks

- [688553.CN](https://longbridge.com/en/quote/688553.CN.md)

## Related News & Research

- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [Orion Pharma to reveal initial results from Phase 1/2 TEADES study of ODM-212 at 2026 ASCO® Meeting.](https://longbridge.com/en/news/287177935.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)